MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.
|Videos|October 11, 2017
How Do You Prescribe for Patients with Beta-Lactam Allergies Without a Skin Test or Allergy Consult?
Author(s)Contagion® Editorial Staff
Christopher McCoy, PharmD, shares the protocol for approaching patients who may have a beta-lactam allergy.
Advertisement
Christopher McCoy, PharmD, associate director of Stewardship at the Beth Israel Deaconess Medical Center shares the protocol for approaching patients who may have a beta-lactam allergy. Dr. McCoy stresses that it’s a combination of reviewing the patient’s electronic medical records, reviewing challenges they’ve experienced in the past, and asking the patient what their allergy history is via interview.
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
4
IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections
5